Why subscribe?

Cannabis Wire publishes uncompromising journalism on the intersection of cannabis policy, regulation, and research. The founders of this news organization are journalists with a decade of experience covering cannabis.

Subscriptions are for people with a professional interest in cannabis, providing quick news and analysis informed by deep expertise and old-fashioned reporting. Our work is not funded by the cannabis industry or any other business that might have interests, which means we can deliver independent reporting and analysis to our subscribers.

Pick the plan that’s right for you

Subscribe now for instant access to news and analysis at the intersection of cannabis policy, regulation, and research, plus databases and our daily newsletter.

What you’ll get Daily Reader All Access
Ad-free reading
Weekly newsletter

A roundup of Cannabis Wire’s most important headlines of the week.
Daily original reporting and analysis
Daily newsletter 

All the extra critical insights, scoops, and analysis you need in one newsletter, leaving you (and, for some, your team) prepared for the day ahead while saving you time. Lands at 7 a.m.
Database Hub access

Cannabis Bill Watch: Cannabis and cannabis-related bills in all 50 states, with summaries, status, and actions.

Global Laws: Detailed information about countries with legal cannabis.

Publicly Traded Companies: A list of publicly traded cannabis companies, and their market caps.

Top Company Profiles: Detailed information about the highest-valued cannabis companies in the world.

Pharma Tracker: Companies focused on cannabis or cannabinoid drug development.

University Hemp and Cannabis Research Centers:
Hemp-focused and Cannabis-focused research centers at universities across the globe.

US State Laws:
Cannabis laws across the United States.
Deeply-researched Cannabis Wire Reports (coming soon)

Stay informed with groundbreaking journalism

Cannabis Wire covers the industry’s influence on politics and policy. Cannabis Wire was the first news organization to report that major companies like Amazon, Altria (maker of Marlboro), Morgan Stanley, Diageo (maker of Guinness, Johnny Walker), and GlaxoSmithKline (maker of Advil, Tums) have all registered to lobby on cannabis.

Our deeply reported analysis connects the dots on national trends, from this three-part series about how the burgeoning industry found new GOP allies in Congress during the Trump administration, to this recent in-depth feature about the narrow window for national cannabis reform under Biden.

And Cannabis Wire’s original reporting goes global, like our piece, co-published with Quartz, with on-the-ground reporting on cannabis in Lesotho.